# Microplate Dx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microplate-dx

- Industry: Biotechnology
- Headquarters: Glasgow, UK
- Website: www.microplatedx.com
- Total disclosed funding: $3.1M
- Latest round: Seed (Apr 4, 2023)
- Investors on record: 5

## About

Based in Glasgow, UK, and founded in 2021 by Dr Stuart Hannah (CEO), Damion Corrigan (CTO), Paul Hoskisson (CSO), and Dr Poonam Malik, Microplate Dx Limited, a.k.a. Microplate Dx operates as a health-tech company that focuses on developing diagnostic solutions to prevent and control the spread of antimicrobial resistance (AMR) worldwide. In September 2023, Microplate Dx Limited raised GBP 2.5 million in seed funding from Deepbridge Capital LLP, the University of Strathclyde, Scottish Enterprise, SIS Ventures, and Thairm Bio.

The company provides an Rplate platform embedded with sensitive biosensor electrodes, modified with miniaturized hydrogel deposits laden with different antibiotics depending on the infection type being measured, for rapid antibiotic susceptibility testing of a patient's sample.

Microplate Dx plans to use its proceeds from September 2023 funding to develop its point-of-care diagnostic platform.

## Funding rounds

- Seed, Apr 4, 2023, $3.1M — University of Strathclyde, Deepbridge Capital, SIS Ventures, Scottish Enterprise, Thairm Bio

## Investors

- University of Strathclyde — Seed
- Deepbridge Capital (https://capitalatlas.ai/funds/deepbridge-capital) — Seed
- SIS Ventures (https://capitalatlas.ai/funds/sis-ventures) — Seed
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Seed
- Thairm Bio — Seed